Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Anti-Inflammation in AD: PET Imaging Supplement
Authors not listed
University of California, Los Angeles · 2000
Abstract
The purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study will also evaluate genetic risk and brain structure as potential predictors of mental decline.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2000). Anti-Inflammation in AD: PET Imaging Supplement. <em>University of California, Los Angeles</em>. https://clinicaltrials.gov/study/NCT00065169
Vancouver
Anonymous. Anti-Inflammation in AD: PET Imaging Supplement. University of California, Los Angeles. 2000.
BibTeX
@misc{anon2000AntiIn,
title = {Anti-Inflammation in AD: PET Imaging Supplement},
author = {Anonymous},
journal = {University of California, Los Angeles},
year = {2000},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Eli Lilly and Company 2014
Open access · US-GOV
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
National Institute on Aging (NIA) 2004
Open access · US-GOV
Clinical Correlates of Longitudinal PET Changes in Alzheimer's Disease (AD)
Neurochemical Research 1995
Citation only
Neural membrane phospholipids in alzheimer disease
New York State Psychiatric Institute 2010
Open access · US-GOV
BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease
Murielle Surquin 2016
Open access · US-GOV
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters
Judit Pich Martínez 2015
Open access · US-GOV